A phase II clinical trial to study the use of cabozantinib (cabo) in patients with hepatocellular carcinoma (HCC) post immunotherapy treatment.

Authors

Stephen Chan

Stephen Lam Chan

State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong, China;

Stephen Lam Chan , Baek-Yeol Ryoo , Frankie Mo , Jaekyung Cheon , Leung Li , Kwan H. Wong , Nicole Yim , Hyeyeong Kim , Changhoon Yoo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04588051

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 571)

DOI

10.1200/JCO.2023.41.4_suppl.571

Abstract #

571

Poster Bd #

E3

Abstract Disclosures